Stockscreener 앱 받기
26.87
0.07%
0.02
전일 마감가:
$26.85
열려 있는:
$26.85
하루 거래량:
421.62K
Relative Volume:
0.54
시가총액:
$1.34B
수익:
$2.50M
순이익/손실:
$-131.12M
주가수익비율:
-9.451
EPS:
-2.8431
순현금흐름:
$-112.73M
1주 성능:
-3.62%
1개월 성능:
-47.58%
6개월 성능:
-5.55%
1년 성능:
+228.48%
1일 변동 폭
$26.45
$27.49
1주일 범위
$26.16
$29.06
52주 변동 폭
$7.16
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.87 | 1.33B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-10 | 개시 | Mizuho | Outperform |
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
모두보기
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN
Maze Therapeutics Inc. places pharma partnerships in focus as President of R and D moderates Boston panel - Traders Union
What analysts say about Maze Therapeutics Inc stockWeekly Gains Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
MAZE Options Volatility — NASDAQ:MAZE - TradingView — Track All Markets
MAZE Options Chain — NASDAQ:MAZE - TradingView — Track All Markets
MAZE News Today | Why did Maze Therapeutics stock go up today? - MarketBeat
Gainers Report: Is CLVT a play on infrastructure spending2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks - Sahm
Rally Mode: Whats the fair value of Maze Therapeutics Inc stockWeekly Loss Report & Precise Trade Entry Recommendations - baoquankhu1.vn
HC Wainwright Issues Optimistic Estimate for MAZE Earnings - MarketBeat
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial - Streetwise Reports
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks - Insider Monkey
Pharma News: What analysts say about Maze Therapeutics Inc stock2026 Review & Daily Stock Momentum Reports - baoquankhu1.vn
8 Most Oversold Strong Buy-Rated Stocks to Invest In - Insider Monkey
Does Maze Therapeutics Inc have declining or rising EPS2026 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - Yahoo Finance
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock - MarketBeat
Maze Therapeutics (MAZE) executive exercises options and sells 15,000 shares - Stock Titan
Maze Therapeutics (MAZE) SVP sells 2,500 shares after option exercise - Stock Titan
Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE - marketbeat.com
Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock By Investing.com - Investing.com South Africa
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock - Investing.com Canada
Maze Therapeutics (MAZE) CSBO exercises options and sells 7,500 shares - Stock Titan
Paradigm group holds 6.1% of Maze Therapeutics (NASDAQ: MAZE) in Schedule 13G - Stock Titan
Director at Maze (NASDAQ: MAZE) receives 33,417 stock options grant - Stock Titan
Maze Therapeutics (MAZE) director Neil Kumar submits initial Form 3 - Stock Titan
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00 - MarketBeat
Proposed 30,000-share option exercise by MAZE (NASDAQ: MAZE) reported - Stock Titan
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital - The Globe and Mail
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
Support Test: Is Maze Therapeutics Inc forming bullish engulfing patterns2026 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE) - Seeking Alpha
After a 30.8% Drop Over the Past Four Weeks, Here’s What Could Cause Maze Therapeutics, Inc. (MAZE) to Rebound - Bitget
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - Yahoo Finance
Q1 EPS Forecast for Maze Therapeutics Raised by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF) - The Globe and Mail
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Sahm
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829 - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat - marketbeat.com
MAZE Shareholders Are Encouraged to Reach Out to Johnson - GlobeNewswire
Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright - Defense World
Maze Therapeutics 2025 Annual Report: Pipeline, Strategy, and Clinical Program Overview - Minichart
Maze Therapeutics Inc (MAZE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.77%
자본화:
|
볼륨(24시간):